Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China
The treatment of non-small-cell lung cancer (NSCLC) has progressed from histology-oriented cytotoxic therapy to the era of molecular biology-oriented targeted therapy and immunotherapy. As the first tyrosine kinase inhibitor (TKI) targeting the ROS1 pathway, crizotinib is widely used as a first-li...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2024-12-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584141103693824 |
|---|---|
| author | Hua Zhong Jun Lu Mengzhao Wang Baohui Han |
| author_facet | Hua Zhong Jun Lu Mengzhao Wang Baohui Han |
| author_sort | Hua Zhong |
| collection | DOAJ |
| description | The treatment of non-small-cell lung cancer (NSCLC) has progressed from histology-oriented cytotoxic
therapy to the era of molecular biology-oriented targeted therapy and immunotherapy. As the first
tyrosine kinase inhibitor (TKI) targeting the ROS1 pathway, crizotinib is widely used as a first-line regimen
for ROS1-rearranged NSCLC. However, due to the paucity of solid data from randomized, controlled phase
III clinical studies, clinicians often require more systematic, real-world data-based guidance for its optimal
clinical use. As one of the leading countries of real-world research on crizotinib, China has contributed
significantly to data on standardization of the therapeutic use of crizotinib, including its clinical treatment
patterns, the timing and duration of treatment and drug resistance monitoring and management. |
| format | Article |
| id | doaj-art-9c0e8e658b1d4a9fb4ab00579b603b8f |
| institution | Kabale University |
| issn | 2042-6313 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj-art-9c0e8e658b1d4a9fb4ab00579b603b8f2025-01-27T15:32:23ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132024-12-0114210.57264/cer-2024-0043Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from ChinaHua Zhong0https://orcid.org/0009-0003-2680-8497Jun Lu1https://orcid.org/0000-0002-7343-9706Mengzhao Wang2https://orcid.org/0009-0003-9742-9830Baohui Han3https://orcid.org/0009-0002-3777-2621Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Respiratory & Critical Care Medicine, Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, ChinaDepartment of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaThe treatment of non-small-cell lung cancer (NSCLC) has progressed from histology-oriented cytotoxic therapy to the era of molecular biology-oriented targeted therapy and immunotherapy. As the first tyrosine kinase inhibitor (TKI) targeting the ROS1 pathway, crizotinib is widely used as a first-line regimen for ROS1-rearranged NSCLC. However, due to the paucity of solid data from randomized, controlled phase III clinical studies, clinicians often require more systematic, real-world data-based guidance for its optimal clinical use. As one of the leading countries of real-world research on crizotinib, China has contributed significantly to data on standardization of the therapeutic use of crizotinib, including its clinical treatment patterns, the timing and duration of treatment and drug resistance monitoring and management.chinacrizotinibnsclcreal-world studiesros1 |
| spellingShingle | Hua Zhong Jun Lu Mengzhao Wang Baohui Han Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China Journal of Comparative Effectiveness Research china crizotinib nsclc real-world studies ros1 |
| title | Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China |
| title_full | Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China |
| title_fullStr | Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China |
| title_full_unstemmed | Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China |
| title_short | Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China |
| title_sort | real world studies of crizotinib in patients with ros1 positive non small cell lung cancer experience from china |
| topic | china crizotinib nsclc real-world studies ros1 |
| work_keys_str_mv | AT huazhong realworldstudiesofcrizotinibinpatientswithros1positivenonsmallcelllungcancerexperiencefromchina AT junlu realworldstudiesofcrizotinibinpatientswithros1positivenonsmallcelllungcancerexperiencefromchina AT mengzhaowang realworldstudiesofcrizotinibinpatientswithros1positivenonsmallcelllungcancerexperiencefromchina AT baohuihan realworldstudiesofcrizotinibinpatientswithros1positivenonsmallcelllungcancerexperiencefromchina |